Visteon Q3 net income swings to $5 million profit; Q3 net sales rise 6% to $970 million
Bitget2026/10/22 10:57- Visteon swung to third-quarter 2026 net income attributable to shareholders of $5 million from a year-earlier loss.
- Net sales rose 6% year over year to $970 million, supported by strong launch execution and robust customer demand.
- Operating cash flow for the nine months ended September 30 fell 72% year over year to $81 million.
- Third-quarter new business wins totaled $0.9 billion, while product launches included an AI-enabled high-performance compute system for Chery.
- Full-year 2026 net sales guidance increased to $3.8 billion–$3.85 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tom Lee Says Yields Below 5% Mean the AI Selloff Is Nearly Over
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.
Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.
Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again
Citigroup maintains its "Buy" rating on Palantir and raises the target price from $245 to $250.
Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing
As a core manufacturer of AI computing power infrastructure, CoreWeave (CRWV.US) holds orders worth tens of billions and its business is expanding rapidly. However, capital expenditure pressure and financing gaps have become the main concerns of the market.
Crypto prices
More
